Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model.
This study will be presented by Dr. François Briand, Director of Research and Business Development, during the morning poster session on Saturday, May the 12th.

On Saturday May the 12th at 1:00pm, Dr. François Briand will also give the Berman & Levy Award Lecture during the KinMet 2018 meeting, a satellite meeting of ATVB on radiotracers kinetics and metabolism.

The lecture deals with the preclinical evaluation of drugs targeting type 2 diabetes, dyslipidemia, diabetic nephropathy and NASH.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.

 

commodo ipsum justo Curabitur ut efficitur. massa porta. Nullam ipsum libero ultricies